Dordaviprone
Appearance
Clinical data | |
---|---|
Other names | ONC-201 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H26N4O |
Molar mass | 386.499 g·mol−1 |
3D model (JSmol) | |
| |
|
Dordaviprone is an investigational new drug that is being evaluated for the treatment of diffuse intrinsic pontine glioma (a type of brain tumor).[1] It is dopamine receptor D2 antagonist and an allosteric activator of the mitochondrial caseinolytic protease P.[2]
References
[edit]- ^ "Dordaviprone - Chimerix". AdisInsight. Springer Nature Switzerland AG.
- ^ Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, et al. (December 2020). "ONC201 and imipridones: Anti-cancer compounds with clinical efficacy". Neoplasia. 22 (12). New York, N.Y.: 725–744. doi:10.1016/j.neo.2020.09.005. PMC 7588802. PMID 33142238.